Author + information
- Andre Lamy, MD∗ ( and )
- John Eikelboom, MB, BS
- ↵∗DBCVSRI C1-112, 237 Barton Street, East Hamilton, Ontario L8L 2X2, Canada
The COMPASS (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS) coronary artery bypass graft (CABG) substudy (1) involved only 1,448 patients and clearly was not powered to demonstrate a significant effect of treatment on major adverse cardiovascular events (MACE). However, our results demonstrating that the combination of rivaroxaban 2.5 mg twice daily plus aspirin versus aspirin alone produced a consistent reduction in MACE in 965 patients enrolled in COMPASS-CABG and 17,313 not enrolled in COMPASS-CABG (hazard ratio: 0.69 vs. 0.76; p for heterogeneity = 0.82) suggest that the post-CABG population derives similar clinical benefits, even though graft failure was not reduced.
We agree with Dr. Tsilimigras and colleagues about the importance of a full cost-effectiveness analysis of the combination of rivaroxaban 2.5 mg twice daily plus aspirin in the COMPASS trial (2). We have previously presented a cost-analysis (3), and we recently completed a full cost-effectiveness analysis for Canada, United States, France, and Germany and have submitted the manuscript for publication.
Please note: Dr. Eikelboom has received grants and personal fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Janssen, AstraZeneca, Eli Lilly, GlaxoSmithKline, and Sanofi. Dr. Lamy has reported that he has no relationships relevant to the contents of this paper to disclose.
- 2019 American College of Cardiology Foundation
- Lamy A.,
- Eikelboom J.,
- Sheth T.,
- et al.
- ↵Lamy A, on behalf of the COMPASS Investigators. Costs impact rivaroxaban plus aspirin versus aspirin in the COMPASS trial. Paper presented at: 2017 AHA Scientific Sessions; November 14, 2017; Anaheim, CA.